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Abstract
Background: Lyme neuroborreliosis (LNB) can affect both the peripheral (PNS) and the central nervous systems
(CNS); it is caused by the spirochete Borrelia burgdorferi. The neuropeptide substance P (SP) is an important mediator of
both neuroinflammation and blood-brain barrier dysfunction, through its NK1 receptor. Increased levels of SP have been
shown to correlate with cell death. The present study used both ex vivo and in vitro models of experimentation to
determine if the inflammatory mediator production and concomitant cell death caused by exposure of neural tissues
and cells to B. burgdorferi could be attenuated by treatment with a NK1 receptor antagonist.
Methods:We incubated normal rhesus frontal cortex tissue explants (CNS) and primary cultures of rhesus dorsal root
ganglia cells (PNS) with live B. burgdorferi and tested the effectiveness of the NK1 receptor antagonist L703,606 in
attenuating inflammatory immune responses and neuronal and glial damage. Culture supernatants and tissue lysates
were subjected to multiplex ELISA to quantify immune mediators, while the cells were evaluated for apoptosis
by the in situ TUNEL assay. In addition, we identified immune mediators and producer cells in tissue sections
by immunofluorescence staining and confocal microscopy.
Results: Co-incubation of both CNS tissues and PNS cells with the NK1 receptor antagonist attenuated bacterially
induced increases in inflammatory cytokine and chemokine production, particularly, IL-6, CXCL8, and CCL2, and
reduced apoptosis levels. Confocal microscopy confirmed that neurons and glial cells are sources of these immune
mediators. These results suggest that NK1R antagonist treatment is able to reduce downstream pro-inflammatory
signaling, thereby indicating that its systemic administration may slow disease progression.
Conclusions: We propose that SP contributes to neurogenic inflammation in LNB, and provide data to suggest
that an NK1 receptor antagonist may represent a novel neuroprotective therapy.
Keywords: Lyme neuroborreliosis, Borrelia burgdorferi, Substance P, NK1R antagonist, CCL2, IL-6, CXCL8, Apoptosis
Background
Inflammation caused by the spirochete Borrelia burgdor-
feri is an important factor in the pathogenesis of Lyme
neuroborreliosis (LNB) [1]. This form of Lyme disease,
which can affect both the central (CNS) and peripheral
nervous systems (PNS), manifests in 10–15 % of
untreated patients [2]. The invasion of the CNS by B. burg-
dorferi can lead to increased levels of pro-inflammatory
molecules such as IL-6, IL-12, IL-18, and IFN-γ, and the
chemokines CXCL8, CCL2, CXCL11, and CXCL13 [3, 4].
Previously, our laboratory demonstrated that interaction of
B. burgdorferi with tissue sections isolated from rhesus
brain parenchyma and cultured ex vivo induces inflamma-
tory mediators in glial cells, as well as oligodendrocyte and
neuronal apoptosis [5]. We also showed that co-culture in
vitro of B. burgdorferi with cells isolated from rhesus dorsal
root ganglia (chiefly neurons) elicited pro-inflammatory
mediators from these cells and caused neuronal apoptosis
[6]. Moreover, when neurons of a neuronal cell line were
incubated with B. burgdorferi, the neurons died by* Correspondence: philipp@tulane.edu
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apoptosis, but only when purified rhesus microglia were
also present [7]. Microglia are potent mediators of CNS in-
flammation [7] as they act as the primary sensors of danger
signals or altered microenvironment.
Substance P (SP) is an 11-amino acid neuropeptide
and the most abundant member of the tachykinin family
of neuropeptides. SP originates from several cellular
sources such as neurons, endothelial cells, and immuno-
cytes, and is released by peripheral nerve endings and
central terminals of sensory neurons in the CNS [8].
The biological responses to SP are mediated by the
neurokinin-1 receptor (NK1R), a G-protein-coupled re-
ceptor bearing seven transmembrane domains [9]. Previ-
ous studies have shown that SP can synergistically
augment B. burgdorferi-induced expression of COX-2 in
murine microglia [10], and that endogenous SP/NK1R
interactions are required for maximal inflammatory
responses to in vivo challenge with bacteria such as
Neisseria meningitidis or B. burgdorferi [11]. Furthermore,
systemic administration of a specific NK1R antagonist
(L703,606) significantly reduced CNS gliosis, demyelination,
and associated inflammatory cytokine elevations in murine
models of bacterial meningitis [11].
In view of these results, obtained with murine models,
we wished to test the effectiveness of this NK1R antag-
onist (L703,606), in tissues and cells of an animal model
that, unlike the mouse, reproduces all of the signs of
Lyme disease, including neuroborreliosis [12–14]. We
tested if inhibition of SP/NK1R interactions was effective
in attenuating inflammatory immune responses and neur-
onal and glial damage in a non-human primate (NHP)
cortical brain explant ex vivo culture model of B. burgdor-
feri CNS infection, as well as in primary cultures of dorsal
root ganglia (DRG) cells from normal adult rhesus
macaques, as an in vitro model of PNS infection.
The demonstration that inhibition of SP/NK1R inter-
actions ameliorate acute bacterially induced damage
in NHP cortical brain tissue and in PNS neurons is
a significant step in showing that such an approach
could be effective as adjuvant therapy in the context
of antibiotic treatment, to limit neuroinflammation




Frontal cortex tissues for ex vivo experiments were col-
lected from seven rhesus macaques (Macaca mulatta)
that were slated for euthanasia because they had chronic
idiopathic diarrhea or had undergone trauma. Animals
were euthanized by a method consistent with the rec-
ommendations of the American Veterinary Medical
Association’s Panel on Euthanasia.
Incubation of brain slices with B. burgdorferi, and NK1R
antagonist treatment
Freshly collected brain tissue was obtained from the
frontal cortex immediately after euthanasia. The tissue
was sliced into 2-mm sections, and each section was
placed in separate wells of 12-well plates. Each well con-
tained 2 mL of RPMI 1640 medium (BioWhittaker,
Walkersville, MD) supplemented with 10 % FBS, as pre-
viously described [5]. Tissue sections were exposed to
medium alone or to medium with added B. burgdorferi
strain B31 clone 5A19 spirochetes (1 × 107 bacteria/mL)
in the presence or absence of 100 μM NK1R antagonist
(L-703,606 oxalate salt hydrate, Sigma-Aldrich, St. Louis,
MO). The wells that received NK1R antagonist were pre-
treated for 2 h prior to the addition of spirochetes, or
medium alone. Incubation at 37 °C for 4 h was allowed
to proceed in a humidified 5 % CO2 incubator. At the
end of the incubation period, half of the total number of
tissue slices was fixed in 2 % paraformaldehyde and
cryopreserved as described earlier [6]. The other half
was processed to obtain protein lysates, and superna-
tants from whole sections, as described below.
For tissue protein extraction, a ratio of tissue to
CelLytic MT reagent of 1:20 (1 g of tissue/20 mL of re-
agent) containing Protease Inhibitor Cocktail (Sigma) to
a final dilution of 1:400 was added to gentleMACS™ M
tubes (Miltenyi BioTec, San Diego, CA). Tissues were
lysed in a single run using the Protein 1 setting of a gen-
tleMACS™ Dissociator (Miltenyi BioTec) for 53 s and
cooled on ice for 2 min. The lysed tissue was centrifuged
at 3273 ×g for 15 min at 4 °C to pellet the tissue debris.
The protein-containing lysate was decanted and stored
at −80 °C.
Immune mediators in ex vivo culture supernatants and
lysates
The concentrations of cytokines and chemokines present
in the tissue slice culture supernatants and lysates were
quantified using the MILLIPLEX MAP Non-Human
Primate Cytokine Magnetic Bead Panel - Premixed 23
Plex, PCYTMG-40 K-PX23 Cytokine-Chemokine Array
kit (Millipore, Billerica, MA) following the manufac-
turer’s instructions.
Immunofluorescence staining for detection of
intracytoplasmic immune mediators
For in situ analysis of intracytoplasmic immune mediators,
frozen tissue blocks were cryosectioned into 16-μm sec-
tions as previously described [6]. Briefly, permeabilization
and blocking were performed with 0.1 % Triton X-100-
PBS-0.2 % fish-skin gelatin for 30 min, followed by
additional blocking incubation with 10 % goat serum-
PBS-0.2 % fish-skin gelatin for 1 h. The primary antibodies
that were used to label various cell phenotypic markers
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were anti-human 2′,3′-cyclic nucleotide 3′-phospho-
diesterase (CNPase), clone 11-5B mouse IgG1 (Millipore)
at 10 μg/mL, anti-human S-100 (Sigma) at 1:500, anti-
human neuronal protein NeuN, MAB 377 clone A60,
mouse IgG1 (Millipore) at 1:10, anti-human glial fibrillary
acidic protein (GFAP), at 1:200, clone G-A-5 purified
mouse immunoglobulin conjugated to Cy3 (Sigma), and
2 μg/mL of chicken polyclonal anti-human IBA1 antibody
(Aves Labs, Inc., Tigard, OR). Primary antibodies for im-
mune mediators were either anti-human IL-6, mouse
IgG2a at 1:1000 (ProSpec, Ness Ziona, Israel), anti-human
CCL2 rabbit polyclonal IgG ab7814 at 1:50 (AbCam,
Cambridge, MA), or anti-human CXCL8 rabbit polyclonal
IgG at 10 μg/mL (RDI, Flanders, NJ). Isotype controls
(Sigma) at the concentrations of the respective primary
monoclonal antibodies and universal rabbit negative
control (Dako Cytomation, Carpinteria, CA) for rabbit
polyclonals were also included. Incubation with the
primary antibody was followed by secondary antibody
staining conjugated to Alexa 488-FITC (green), Alexa 633
(far red), or Alexa 568 (red) (Molecular Probes, Life
Technology, Inc. Grand Island, NY). Samples were ana-
lyzed on a Leica DMi8 confocal microscope equipped with
three lasers (Leica Microsystem, Exton, PA).
Incubation of DRG cell cultures with B. burgdorferi and
NK1R antagonist treatment
Chamber slides (two wells) with detachable culture
slides were first coated with poly-D lysine (BD Biosci-
ences, Franklin Lakes, NJ) and then laminin (Invitrogen)
at a final concentration of 10 μg/mL for a minimum of
2 h before seeding the cells. Before plating the DRG
cells, the laminin was removed. DRG were obtained
from two adult rhesus macaques at necropsy, minced,
trypsinized in 5 mL of 0.25 % trypsin-EDTA (Invitrogen)
with 1000 units of DNAse (Sigma), pelleted and seeded
at 1 × 105 cells per well. DRG cell cultures were main-
tained for a period of 6 to 7 days in complete DMEM
F12 medium containing 10 % FBS and 1X penicillin/
streptomycin (P/S) supplemented with fresh L-glutamine
(2 mM), and NGF-7S (50 ng/mL, Invitrogen) (complete
medium). The DRG cell culture protocol has been
thoroughly described previously [6].
DRG cell cultures were pre-incubated in complete
medium as above but without P/S, and treated with
10 μM of NK1R antagonist (L-703,606 oxalate salt hy-
drate, Sigma) for 2 h at 37 °C, or left untreated. Cultures
were then stimulated with live B. burgdorferi at a multi-
plicity of infection (MOI) of 10:1 at 37 °C for 24 h. After
24 h, culture supernatants were collected and processed
for quantification of inflammatory mediators, and cells
were fixed and evaluated for apoptosis by the TUNEL
assay as described below. Medium controls that were
pre-treated and then incubated with the same respective
concentrations of NK1R antagonist but without the
addition of live B. burgdorferi were also included.
Apoptosis by in situ TUNEL assay
Tissue slides as well as DRG cell culture chamber slides
were incubated with anti-NeuN or anti-S-100 antibodies
prior to performing the TUNEL assay. Slides were then
subjected to the TUNEL-ApopTagPlus fluorescein in situ
apoptosis assay (Chemicon, Temecula, CA) as per the
manufacturer’s instructions. The percentage of apoptotic
neurons in brain sections and DRG cell cultures, or the
percentage of apoptotic oligodendrocytes in brain sec-
tions, was evaluated by counting at least 500 cells in ten
microscope fields, followed by the percentage of cells
that showed co-localization of both the TUNEL signal
and NeuN or S-100 expression. Cells were counted by
viewing slides under a fixed magnification of 40x using
Nuance Multispectral Imaging System (CRi, PerkinEl-
mer, Waltham, MA). The identity of the oligodendro-
cytes that stained with the anti-S-100 antibody was
confirmed by their morphology.
Statistical evaluation
The unpaired-two tailed t test was used to evaluate the
statistical significance between means of data sets, using
Graphpad Prizm software (Graph Pad Software Inc., La
Jolla, CA) version 5a. A p value of 0.05 or lower was
considered to be statistically significant.
Results
Analysis of SP/NK1R interactions in the ex vivo model of
CNS infection
Quantification of pro-inflammatory mediators
Interaction of B. burgdorferi with rhesus macaque brain
parenchyma sections cultured ex vivo elicited IL-6,
CXCL8, and CCL2 production that was detectable in
both lysate and supernatant, as determined by the NHP
Cytokine 23 BioPlex Panel. The addition of NK1R antag-
onist significantly reduced these inflammatory cytokine
levels, albeit with animal-to-animal variations (Fig. 1).
This pattern of response was seen both in the tissue
lysates and tissue section supernatants. It suggests
that SP receptor antagonist is able to significantly re-
duce inflammation derived from the presence of B.
burgdorferi within the CNS.
Quantification of apoptosis
We next evaluated the likely impact of B. burgdorferi-in-
duced inflammation in the induction of apoptosis. As in
previous studies [1], we found oligodendrocytes under-
going apoptosis (Fig. 2). Importantly, there was a signifi-
cant reduction in the amount of B. burgdorferi-induced
apoptosis in the presence of NK1R antagonist.
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Neuronal cell death was also evaluated, and overall,
the level of neuronal apoptosis was much lower than
that seen in oligodendrocytes (less than 2 % in frontal
cortex tissues exposed to B. burgdorferi for 4 h). In
addition, there were no significant differences in the re-
duction in the level of B. burgdorferi-induced apoptosis
in the presence of NK1R antagonist (data not shown).
Cellular sources of pro-inflammatory mediators
We focused on the cellular sources of IL-6, CXCL8, and
CCL2. Interaction of B. burgdorferi with rhesus monkey
brain parenchyma sections elicited IL-6 production by
several types of glial cells, namely, astrocytes, oligoden-
drocytes, neurons, and microglia. CXCL8 and CCL2
were not found to be produced by neurons and
microglia, respectively, but were present in the other cell
types (Table 1 and Fig. 3).
Analysis of SP/NK1R interactions in primary cultures of
rhesus dorsal root ganglia cells
Quantification of pro-inflammatory mediators
In previous studies, cells that were isolated from rhesus
DRG and exposed to live B. burgdorferi in vitro, were
shown to produce pro-inflammatory mediators, and
DRG neurons were shown to undergo apoptosis [6]. To
ascertain the effect of SP/NK1R interactions in cells of
the PNS, we set up primary cultures of DRG cells from
normal adult rhesus macaques and incubated the cul-
tures with B. burgdorferi (MOI 10:1) for 24 h in the
presence or absence of 10 μM NK1R antagonist. Results
Fig. 1 Pro-inflammatory mediator levels in the supernatants and lysates of rhesus macaque frontal cortex sections cultured ex vivo. IL-6 (a), CXCL8
(b), and CCL2 (c) levels were determined by multiplex ELISA in brain tissues that were exposed to B. burgdorferi (Bb), medium alone (Med), B.
burgdorferi plus NK1R antagonist (Bb + A), or medium alone plus antagonist (Med + A). The figure shows the arithmetic means ± standard deviations
of experimental replicates for each individual animal. **p < 0.001, ***p < 0.0001, ns not significant
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obtained with the Multiplex cytokine assay from two
different biological replicates consistently showed that
the interaction of B. burgdorferi with rhesus DRG cells
elicited IL-6, CXCL8, CCL2, and VEGF. The addition of
NK1R antagonist was able to significantly reduce the
level of CCL2. The levels of the other mediators were
also reduced, albeit not significantly (Fig. 4).
Quantification of apoptosis
B. burgdorferi-induced apoptosis of sensory neurons in
the DRG cultures, and addition of the NK1R antagonist
at a concentration of 100 nM significantly reduced the
level of neuronal apoptosis (p < 0.001; Fig. 5).
Discussion
Recently, using a NHP model of acute LNB, it was dem-
onstrated that inflammation plays a key role in LNB
pathogenesis [15]. Moreover, in a murine model, it was
shown that SP, which is present throughout the CNS
and is the most abundant tachykinin in the brain [16],
increases inflammatory mediator production by astrocytes
and microglia following exposure to either Neisseria
meningitidis or B. burgdorferi [11]. These findings set the
scene to investigate the immunoregulatory effects of SP/
NK1R interactions in NHP cortical brain tissue and PNS
neurons exposed to B. burgdorferi.
We have shown that co-incubation of both CNS tis-
sues and PNS cells with the NK1R antagonist L703,606
attenuates bacterially induced increases in inflammatory
cytokine and chemokine production, particularly IL-6,
CXCL8, and CCL2 (Figs. 1 and 4), and reduces apoptosis
levels of neural cells (Figs. 2 and 5). In addition, using
confocal microscopy, we identified cellular sources of
these immune mediators (Table 1 and Fig. 3) and con-
firmed that they are produced by glial cells and neurons
[4]. These results suggest that NK1R antagonist treat-
ment is able to reduce downstream pro-inflammatory
signaling, thereby indicating that its systemic administra-
tion may slow down disease progression.
SP is a potent initiator of neurogenic inflammation in
the CNS, an effect that is often followed by alterations
in blood-brain barrier permeability and by persistent
neurological deficits [10, 17]. The neuroinvasion that
manifests in CNS neuroborreliosis depends on the suc-
cessful translocation of spirochetes across the blood-
brain barrier [18] and is concomitant with SP release
[10]. We propose that the exacerbation of SP levels may
accelerate disease progression, since blockage of NK1R
in our ex vivo and in vitro models limits inflammation
and improves cell survival. These results agree with the
reported effects of NK1R antagonist treatment, which
protected dopaminergic neurons, preserved barrier in-
tegrity, reduced neuroinflammation, and significantly
improved motor function in a rat model of early Parkin-
son’s disease [19].
Results obtained from the interaction of B. burgdorferi
with rhesus DRG cells indicate that activation of NK1R
by SP can stimulate the chemokine CCL2. This
Table 1 Phenotypes of immune mediator producer cells as
visualized by confocal microscopy
IL-6 CXCL8 CCL2
Neuron (NeuN) + − +
Astrocyte (GFAP) + + +
Oligodendrocyte (CNPase) + + +
Microglia (IBA-1) + + −
Fig. 2 Neural cell apoptosis in rhesus frontal cortex tissue sections cultured ex vivo. a S-100-positive cells (oligodendrocytes, as identified by
morphology) and DNA fragmentation detected by the TUNEL assay in green, as visualized by fluorescent microscopy. b Graphical representation of
the percent apoptosis as detected by the TUNEL assay in frontal cortex tissue exposed for 4 h to B. burgdorferi (Bb), exposed to B. burgdorferi and
treated with NK1R antagonist (Bb + A), in medium alone (Med), and medium with added NK1R antagonist (Med + A) (***p < 0.0001, ns not significant)
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chemokine plays a fundamental role in inflammation by
recruiting inflammatory cells to specific sites [20], and
we speculate that stimulation of CCL2 by SP can poten-
tially mediate this recruitment in vivo. In addition, NK1R
antagonist modestly reduced IL6, CXCL8, and VEGF
production by DRG cells, following the same pattern as
with CCL2. However, this phenomenon was not statisti-
cally significant (Fig. 4). SP induces a non-apoptotic
form of cell death in hippocampal, striatal, and cortical
neurons and thus plays an important role in pathological
Fig. 3 Visualization of IL-6, CXCL8, and CCL2. a IL-6 (green) inside neurons stained red with anti-NeuN antibody. b CCL2 (green) inside neurons
that were stained red with anti-NeuN antibody. c IL-6 (green) and astrocytes stained red with anti-GFAP antibody. d CXCL8 (green) and astrocytes
stained red. The yellow signal is due to co-localization of the astrocytic marker GFAP (red) and IL-6 or CXCL8 (green) within astrocytes. e CCL2
(green) inside astrocytes stained red. f, g Evidence of IL-6 and CXCL8 (green) in microglia stained with anti-IBA1 antibody (red)
Martinez et al. Journal of Neuroinflammation  (2015) 12:243 Page 6 of 9
states in which neural cell death occurs [21]. Our results
indicate that SP/NK1R interactions can also induce
apoptotic cell death, as NK1R antagonist treatment
prevented DRG neuronal apoptosis (Fig. 5). Taken
together, these data suggest that the NK1R, in addition
to modulating inflammation, may be a mediator of cell
death in vivo.
We hypothesized that SP contributes to the patho-
physiology of neuroborreliosis, and we evaluated this hy-
pothesis with NK1R-expressing CNS tissues. Indeed, our
results showed that both secreted and intracellular pro-
inflammatory proteins were suppressed in the presence
of NK1R antagonist (Fig. 1), albeit with animal-to-animal
variation, in our ex vivo culture model of B. burgdorferi
CNS infection. We also found an anti-apoptotic effect
in oligodendrocytes that was mediated by the NK1R
antagonist (Fig. 2), but not in neurons. Oligodendro-
cytes are vital for the functioning and survival of neu-
rons, and the inflammation and subsequent apoptosis
of oligodendrocytes induced by B. burgdorferi could
contribute to the pathogenesis of LNB [1].
Previous studies have shown that NK1R signaling plays
a role in numerous biological processes, such as the
transmission of pain in the spinal cord [22, 23]. Activa-
tion of NK1R by SP leads to phosphoinositide hydrolysis,
calcium mobilization, and mitogen-activated protein kin-
ase (MAPK) activation [24, 25], and regulates neuroin-
flammation, neuronal survival, and synaptic activity [21].
Our results agree with this general picture, as they sug-
gest that NK1R/SP interaction contributes to the devel-
opment of B. burgdorferi-induced inflammation in the
CNS and PNS. This interaction thus represents a thera-
peutic target for neuroinflammation.
Fig. 4 Pro-inflammatory mediator levels in supernatants from rhesus
DRG cultures. IL-6, CXCL8, CCL2, and VEGF levels were detected by
Multiplex ELISA in cells exposed to B. burgdorferi (Bb) or medium
alone (Med), and treated with NK1R antagonist in the presence
(Bb + A) or absence of B. burgdorferi (Med + A). The figure shows
the arithmetic means ± standard deviations from two biological
replicates. **p < 0.001, ns not significant
Fig. 5 Apoptosis in DRG cell cultures. a Non-apoptotic field of neurons (NeuN-positive cells, red) cultured from rhesus DRG as visualized by
fluorescent microscopy. b DNA fragmentation detected by the TUNEL assay (green) as visualized by fluorescent microscopy. c Graphical representation
of the percent neuronal apoptosis as quantified by the TUNEL assay in cultured DRG cells exposed for 24 h to B. burgdorferi (Bb), exposed to B.
burgdorferi, and treated with NK1R antagonist (Bb + A), in medium alone (Med), and medium plus antagonist (Med + A) (**p < 0.001)
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From the pertinent literature, it is evident that SP is an
important mediator of inflammatory responses and
pathological conditions associated with inflammation,
including rheumatoid arthritis, multiple sclerosis, in-
flammatory bowel disease, lymphatic contractility, and
pneumococcal meningitis [26–30]. In our present model,
inflammation mediated by SP/NK1R likely results from
the synergistic effect of this interaction on the neural cell
response to B. burgdorferi. We suggest that endogenous
SP augments B. burgdorferi-associated pathology within
the brain by elevating levels of inflammatory mediators
and by promoting cell death probably though activation
of the MAPK signaling cascade [31]. We have shown
previously that the MEK/ERK pathway is crucial for B.
burgdorferi-induced inflammation and P53-mediated
apoptosis in oligodendrocytes [32].
The molecular mechanisms leading to inflammatory
mediator release from the resident cells of the CNS
when exposed to B. burgdorferi are numerous and are
currently being investigated in our laboratory. Recently,
several studies have shown that multiple receptors and
pathways positively and negatively regulate microglial
inflammation, resulting in a complex immune network
[32–34]. CCL2/CCR2 and MAPK signaling, chiefly MEK/
ERK, play a major role in neuroinflammation [32, 35], and
our results are consistent with the possibility that blockage
of NK1R may act by limiting these signaling cascades.
Thus, in addition to antibiotics, treatment with NK1R
antagonists could be explored as an adjuvant intervention
against LNB.
Conclusions
Our results indicate that NK1R antagonist treatment can
attenuate bacterially induced increases of inflammatory
mediator production in CNS and PNS cells, particularly,
IL-6, CXCL8, and CCL2, as well as apoptosis levels.
Abbreviations
CCL2: chemokine (C-C) motif ligand 2; CCR2: C-C chemokine receptor 2;
CNPase: 2′, 3′- cyclic nucleotide 3′-phosphodiesterase; CNS: central nervous
system; CSF: cerebrospinal fluid; DRG: dorsal root ganglia; FBS: fetal bovine
serum; GFAP: glial fibrillary acidic protein; IFN-γ: interferon gamma; LNB:
Lyme neuroborreliosis; MOI: multiplicity of infection; NeuN: neuronal nuclear
protein N; NGF: nerve growth factor; P/S: penicillin and streptomycin;
PBS: phosphate-buffered saline; PNS: peripheral nervous system; TUNEL: terminal
deoxynucleotidyl transferase-mediated UTP nick end labeling; VEGF: vascular
endothelial growth factor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ANM participated in the design of the experiments, conducted cell culture
of DRG, ex vivo brain cortex tissue explant experiments, multiplex ELISA data
analysis, immunofluorescence staining and confocal microscopy, and drafted
the manuscript. GR helped in DRG cell culture, immunofluorescence staining,
and microscopy imaging. MBJ helped in establishing and counting B. burgdorferi
cell cultures. MTP conceived of the study, contributed to the design of the
experiments, and to drafting and editing the manuscript. All authors have read
and approved the final version of the manuscript.
Acknowledgements
This project was supported by the National Institute of Neurologic Disorders
and Stroke through grant NS 050325 and by the National Center for
Research Resources and the Office of Research Infrastructure Programs
(ORIP) of the National Institutes of Health through grant P51OD011104/
P51RR000164. We thank the TNPRC Pathogen Detection and Quantification
Core Laboratory for help with the multiplex ELISA assays. Robin Rodriguez
from the TNPRC Media Laboratory is gratefully acknowledged for assisting
with formatting the figures.
Received: 10 November 2015 Accepted: 5 December 2015
References
1. Ramesh G, Benge S, Pahar B, Philipp MT. A possible role for inflammation in
mediating apoptosis of oligodendrocytes as induced by the Lyme disease
spirochete Borrelia burgdorferi. J Neuroinflammation. 2012;9:72.
2. Halperin JJ. Nervous system Lyme disease. Curr Infect Dis Rep. 2015;17:445.
3. Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the
crossroads of neuroinflammation, neurodegeneration, and neuropathic pain.
Mediators Inflamm. 2013;2013:480739.
4. Kondrusik M, Swierzbińska R, Pancewicz S, Zajkowska J, Grygorczuk S,
Hermanowska-Szpakowicz T. [Evaluation of proinflammatory cytokine
(TNF-alpha, IL-1beta, IL-6, IFN-gamma) concentrations in serum and
cerebrospinal fluid of patients with neuroborreliosis]. Neurol Neurochir Pol.
2004;38:265–70.
5. Ramesh G, Borda JT, Dufour J, Kaushal D, Ramamoorthy R, Lackner AA, et al.
Interaction of the Lyme disease spirochete Borrelia burgdorferi with brain
parenchyma elicits inflammatory mediators from glial cells as well as glial
and neuronal apoptosis. Am J Pathol. 2008;173:1415–27.
6. Ramesh G, Santana-Gould L, Inglis FM, England JD, Philipp MT. The
Lyme disease spirochete Borrelia burgdorferi induces inflammation
and apoptosis in cells from dorsal root ganglia. J Neuroinflammation.
2013;10:88.
7. Myers TA, Kaushal D, Philipp MT. Microglia are mediators of Borrelia
burgdorferi-induced apoptosis in SH-SY5Y neuronal cells. PLoS Pathog.
2009;5:e1000659.
8. Vilisaar J, Kawabe K, Braitch M, Aram J, Furtun Y, Fahey AJ, Chopra M,
Tanasescu R, Tighe PJ, Gran B, Pothoulakis C, Constantinescu CS. Reciprocal
regulation of substance P and IL-12/IL-23 and the associated cytokines,
IFNγ/IL-17: A perspective on the relevance of this interaction to multiple
sclerosis. J Neuroimmune Pharmacol. 2015.
9. Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW.
Tachykinins and their receptors: contributions to physiological control and
the mechanisms of disease. Physiol Rev. 2014;94(1):265–301.
10. Rasley A, Marriott I, Halberstadt CR, Bost KL, Anguita J. Substance P
augments Borrelia burgdorferi-induced prostaglandin E2 production by
murine microglia. J Immunol. 2004;172:5707–13.
11. Chauhan VS, Sterka DG, Gray DL, Bost KL, Marriott I. Neurogenic
exacerbation of microglial and astrocyte responses to Neisseria meningitidis
and Borrelia burgdorferi. J Immunol. 2008;180:8241–9.
12. Roberts ED, Bohm RP, Lowrie RC, Habicht G, Katona L, Piesman J, et al.
Pathogenesis of Lyme neuroborreliosis in the rhesus monkey: the early
disseminated and chronic phases of disease in the peripheral nervous
system. J Infect Dis. 1998;178:722–32.
13. Philipp MT, Johnson BJ. Animal models of Lyme disease: pathogenesis and
immunoprophylaxis. Trends Microbiol. 1994;2:431–7.
14. Pachner AR, Gelderblom H, Cadavid D. The rhesus model of Lyme
neuroborreliosis. Immunol Rev. 2001;183:186–204.
15. Ramesh G, Didier PJ, England JD, Santana-Gould L, Doyle-Meyers LA, Martin
DS, et al. Inflammation in the pathogenesis of Lyme neuroborreliosis. Am J
Pathol. 2015;185:1344–60.
16. Marriott I. The role of tachykinins in central nervous system inflammatory
responses. Front Biosci. 2004;9:2153–65.
17. Turner RJ, Vink R. NK1 tachykinin receptor treatment is superior to capsaicin
pre-treatment in improving functional outcome following acute ischemic
stroke. Neuropeptides. 2014;48:267–72.
18. Mlynarcik P, Pulzova L, Bencurova E, Kovac A, Dominguez MA, Hresko S,
et al. Deciphering the interface between a CD40 receptor and borrelial
ligand OspA. Microbiol Res. 2015;170:51–60.
Martinez et al. Journal of Neuroinflammation  (2015) 12:243 Page 8 of 9
19. Thornton E, Vink R. Treatment with a substance P receptor antagonist is
neuroprotective in the intrastriatal 6-hydroxydopamine model of early
Parkinson’s Disease. PLoS One. 2012;7:e34138.
20. Castellani ML, Vecchiet J, Salini V, Conti P, Theoharides TC, Caraffa A, et al.
Stimulation of CCL2 (MCP-1) and CCL2 mRNA by substance P in LAD2
human mast cells. Transl Res. 2009;154:27–33.
21. Castro-Obregón S, Del Rio G, Chen SF, Swanson RA, Frankowski H, Rao RV,
et al. A ligand-receptor pair that triggers a non-apoptotic form of
programmed cell death. Cell Death Differ. 2002;9:807–17.
22. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and
pathophysiological roles. Neuropeptides. 1998;32:1–49.
23. Weisshaar CL, Winkelstein BA. Ablating spinal NK1-bearing neurons
eliminates the development of pain and reduces spinal neuronal
hyperexcitability and inflammation from mechanical joint injury in the
rat. J Pain. 2014;15:378–86.
24. Rosso M, Muñoz M, Berger M. The role of neurokinin-1 receptor in the
microenvironment of inflammation and cancer. Sci World J. 2012;2012:1–21.
25. Bouzas-Rodríguez J, Zárraga-Granados G, Sánchez-Carbente Mdel R,
Rodríguez-Valentín R, Gracida X, Anell-Rendón D, et al. The nuclear
receptor NR4A1 induces a form of cell death dependent on autophagy in
mammalian cells. PLoS One. 2012;7:e46422.
26. Makino A, Sakai A, Ito H, Suzuki H. Involvement of tachykinins and NK1
receptor in the joint inflammation with collagen type II-specific monoclonal
antibody-induced arthritis in mice. J Nippon Med Sch. 2012;79:129–38.
27. Reinke EK, Johnson MJ, Ling C, Karman J, Lee J, Weinstock JV, et al.
Substance P receptor mediated maintenance of chronic inflammation in
EAE. J Neuroimmunol. 2006;180:117–25.
28. Nessler S, Stadelmann C, Bittner A, Schlegel K, Gronen F, Brueck W, et al.
Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor
antagonist—a putative role for substance P in CNS inflammation. J
Neuroimmunol. 2006;179:1–8.
29. Chakraborty S, Nepiyushchikh Z, Davis MJ, Zawieja DC, Muthuchamy M.
Substance P activates both contractile and inflammatory pathways in
lymphatics through the neurokinin receptors NK1R and NK3R. Microcirculation.
2011;18:24–35.
30. Chauhan VS, Kluttz JM, Bost KL, Marriott I. Prophylactic and therapeutic
targeting of the neurokinin-1 receptor limits neuroinflammation in a murine
model of pneumococcal meningitis. J Immunol. 2011;186:7255–63.
31. Castro-Obregon S, Rao RV, del Rio G, Chen SF, Poksay KS, Rabizadeh S, et al.
Alternative, nonapoptotic programmed cell death: mediation by arrestin 2,
ERK2, and Nur77. J Biol Chem. 2004;279:17543–53.
32. Parthasarathy G, Philipp MT. The MEK/ERK pathway is the primary conduit
for Borrelia burgdorferi-induced inflammation and P53-mediated apoptosis
in oligodendrocytes. Apoptosis. 2014;19:76–89.
33. Ramesh G, Philipp MT, Vallières L, MacLean AG, Ahmad M. Mediators of
neuroinflammation. Mediators Inflamm. 2013;2013:314261.
34. Parthasarathy G, Philipp MT. Inflammatory mediator release from primary
rhesus microglia in response to Borrelia burgdorferi results from the
activation of several receptors and pathways. J Neuroinflammation.
2015;12:60.
35. Maddahi A, Edvinsson L. Cerebral ischemia induces microvascular
pro-inflammatory cytokine expression via the MEK/ERK pathway. J
Neuroinflammation. 2010;7:14.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Martinez et al. Journal of Neuroinflammation  (2015) 12:243 Page 9 of 9
